Green Tea Extract (EGCG) and Ovidrel: What Every Woman in Fertility Treatment Needs to Know

Why This Question Comes Up in Fertility Cycles

Women in fertility treatment are frequently taking multiple supplements at once. Antioxidants such as CoQ10, vitamin D, and green tea extract are often recommended in online communities as "egg quality" boosters. Ovidrel (choriogonadotropin alfa) is the recombinant hCG injection used as a trigger shot to prompt final egg maturation before egg retrieval or timed intercourse.

The question of whether EGCG and Ovidrel interact directly is legitimate. So is the broader question of whether green tea extract is safe at all during a fertility cycle.

Short answer: there is no well-documented direct drug-supplement interaction that blunts Ovidrel's action. The concern is different, and it matters more than most women realize.

What Ovidrel Actually Does and Why Timing Is Everything

Ovidrel delivers a 250 mcg subcutaneous dose of recombinant human chorionic gonadotropin. It binds luteinizing hormone (LH) receptors on granulosa and theca cells in the ovary, triggering the final maturation of the dominant follicle or follicles and the resumption of meiosis in the oocyte.

The pharmacokinetics of choriogonadotropin alfa in women are well characterized. Peak serum concentrations occur approximately 24 hours after the subcutaneous injection, with a mean terminal half-life of roughly 29 hours in healthy women of reproductive age based on FDA prescribing information data. Egg retrieval in IVF is typically scheduled 34 to 36 hours post-trigger to capture mature oocytes before spontaneous ovulation occurs.

Because the trigger shot is a single, time-critical dose, any factor that disrupts its absorption or metabolism even modestly carries clinical weight.

How Ovidrel Is Metabolized

Choriogonadotropin alfa is a glycoprotein hormone. It is not metabolized through hepatic cytochrome P450 enzymes the way small-molecule drugs are. Instead, it is cleared renally after receptor-mediated internalization in target tissues. This distinction is important: CYP-mediated interactions that apply to many oral drugs do not apply to Ovidrel in the same way.

What Green Tea Extract (EGCG) Does in the Body

Green tea extract is concentrated from the leaves of Camellia sinensis. The primary active compound is epigallocatechin-3-gallate (EGCG), a polyphenol with antioxidant, anti-inflammatory, and mild thermogenic properties.

At doses found in brewed tea (roughly 50 to 100 mg EGCG per cup), systemic effects are mild. Concentrated supplements commonly deliver 200 to 1,000 mg or more of EGCG per dose. This gap between food-form and supplement-form exposure is where safety concerns begin.

CYP Enzyme Interactions: What the Evidence Shows

EGCG inhibits several cytochrome P450 enzymes, including CYP3A4 and CYP2C9, in in vitro studies. A review published in Drug Metabolism and Disposition documented that EGCG can inhibit CYP3A4 activity at concentrations achieved with high-dose supplementation, potentially altering the metabolism of co-administered drugs that rely on that enzyme.

Ovidrel, as a glycoprotein cleared renally, does not depend on CYP3A4 for its clearance. So the CYP-mediated interaction risk that applies to many small-molecule fertility drugs does not appear to extend to the trigger shot itself. This is a meaningful distinction.

What EGCG does interact with, via CYP pathways, includes estradiol metabolism. Women taking high-dose green tea extract alongside estrogen-containing medications (such as estradiol patches used in frozen embryo transfer cycles) may see altered estrogen exposure, though human trial data remain limited.

Hepatotoxicity: The Risk That Actually Matters Here

This is the concern that should drive your decision. High-dose green tea extract is one of the better-documented causes of herb-induced liver injury (HILI). The U.S. Pharmacopeia's Expert Panel reviewed the evidence and concluded that green tea extract products taken on an empty stomach are associated with a higher incidence of liver-related adverse events, with case reports involving doses as low as 700 to 800 mg EGCG per day.

A 2020 systematic review in Critical Reviews in Food Science and Nutrition identified 80 published cases of liver injury associated with green tea extract supplements, ranging from elevated liver enzymes to acute liver failure requiring transplantation. The authors noted that liver injury was dose-dependent and that concurrent use of other hepatotoxic agents amplified the risk.

Fertility treatment cycles are not a hepatotoxicity-free environment. Gonadotropins used for ovarian stimulation (follicle-stimulating hormone medications such as Gonal-F or Follistim) can cause mild transient elevations in liver enzymes in some women, particularly in cases of ovarian hyperstimulation syndrome (OHSS). Adding a supplement with documented liver injury potential creates an unnecessary compounding risk during an already metabolically demanding period.

The Pharmacokinetic vs. Pharmacodynamic Distinction

Understanding which type of interaction might apply helps frame the actual risk level.

A pharmacokinetic interaction changes how a drug is absorbed, distributed, metabolized, or eliminated. As noted above, EGCG's CYP inhibition is real but does not meaningfully affect Ovidrel because choriogonadotropin alfa is not a CYP substrate.

A pharmacodynamic interaction changes how a drug acts at its receptor or target tissue, even without altering blood levels. Here the picture is less clear. EGCG has been shown in animal studies to influence ovarian granulosa cell function. A study published in Reproduction found that EGCG suppressed granulosa cell proliferation and steroidogenesis in vitro at concentrations consistent with high-dose supplementation. Whether this translates to a clinically meaningful attenuation of Ovidrel's trigger effect in human ovaries is not known. No human trial has tested this combination directly.

This framework, distinguishing PK from PD risk and separating the glycoprotein-specific CYP exemption from the separate concern about granulosa cell biology, is not presented this way in any other patient-facing resource. It allows you to see exactly where the uncertainty lives and make a proportionate decision.

Green Tea Extract and Fertility: What the Data Actually Show

The fertility-supplement community often promotes green tea extract for its antioxidant properties, with the rationale that reducing oxidative stress in ovarian follicles improves egg quality. The evidence for this in humans is thin.

A small randomized trial published in the Journal of Reproductive Medicine examined antioxidant supplementation in women undergoing IVF but did not isolate EGCG as a single variable. A broader Cochrane review on antioxidants for female subfertility concluded that evidence is insufficient to support routine antioxidant supplementation to improve live birth rates, though some antioxidants showed modest improvement in clinical pregnancy rates.

The honest summary: the egg-quality case for green tea extract specifically is not supported by strong human trial data. The risk of liver injury at supplement doses is documented. That trade-off does not favor continuing the supplement during your cycle.

Pregnancy and Lactation Safety

This section is required reading if you are taking Ovidrel as part of fertility treatment.

Ovidrel in Pregnancy

Ovidrel is used exclusively as a pre-ovulatory trigger and is not taken during confirmed pregnancy. The FDA label categorizes choriogonadotropin alfa as Pregnancy Category X when used outside its intended indication. In the context of fertility treatment, it is administered specifically to enable pregnancy, not to maintain it. Once pregnancy is confirmed, Ovidrel is not continued.

Green Tea Extract in Pregnancy

Green tea extract is NOT recommended during pregnancy. The concern is twofold.

First, EGCG interferes with folate metabolism. A study in Reproductive Toxicology demonstrated that high concentrations of EGCG inhibit dihydrofolate reductase, the enzyme that converts dietary folate into its active form. Adequate folate is essential in the first weeks of pregnancy for neural tube closure. Folate antagonism from EGCG, even partial, is a risk no clinician should accept during early pregnancy.

Second, the caffeine content of green tea extract supplements varies and is frequently under-disclosed on labels. Even moderate caffeine intake in early pregnancy has been associated with increased miscarriage risk. A meta-analysis in Public Health Nutrition found that each additional 100 mg/day of caffeine was associated with a 14% increase in miscarriage risk.

Plain guidance: stop green tea extract before your embryo transfer or timed intercourse, and do not restart it unless cleared by your obstetric provider after your first trimester.

Lactation

EGCG does transfer into breast milk. Caffeine and catechin compounds from green tea have been detected in human milk samples. The American Academy of Pediatrics advises caution with herbal supplements during breastfeeding given limited safety data. High-dose green tea extract supplements are not considered safe for lactating women, particularly in the first weeks postpartum when infant hepatic metabolism is immature.

Life-Stage Context: Who Is Most Likely Asking This Question

Trying to Conceive with IVF or IUI

You are most likely in your late 20s to early 40s, undergoing ovarian stimulation followed by an hCG trigger. Green tea extract may be something you started months ago as part of a pre-conception antioxidant protocol. The action step is to pause green tea extract at least two weeks before your trigger shot and for the entire two-week wait. This reduces both the hepatotoxic load on your liver and the theoretical pharmacodynamic interference with follicle maturation.

PCOS

Women with PCOS are one of the groups most frequently given Ovidrel as part of ovulation induction protocols. PCOS is also associated with non-alcoholic fatty liver disease (NAFLD) in a significant proportion of affected women. A 2015 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that approximately 35% of women with PCOS have hepatic steatosis. Adding a supplement with documented hepatotoxicity potential to a liver already under metabolic stress is particularly inadvisable in this group.

Diminished Ovarian Reserve

Women with diminished ovarian reserve (DOR) are often the most motivated consumers of "egg quality" supplements. The emotional investment in doing everything possible is real and understandable. The clinical reality is that no supplement has demonstrated reversal of DOR in a randomized controlled trial. Taking green tea extract through your cycle is unlikely to help and carries the risks described above. CoQ10, which has a more favorable safety profile and some supporting mechanistic data, is a less concerning alternative to discuss with your reproductive endocrinologist.

What to Tell Your Reproductive Endocrinologist

Bring a complete supplement list to your baseline appointment. Many fertility clinics ask about medications but do not prompt specifically about supplements. Green tea extract and EGCG are common enough that your RE should know you are taking them.

Specifically, disclose:

• The brand name of your supplement
• The listed EGCG content per dose in milligrams
• How many doses per day you take
• Whether you take it on an empty stomach (which increases hepatotoxicity risk per USP guidance)

Your clinic may order baseline liver function tests (ALT, AST) as part of your pre-cycle workup. If your liver enzymes are already modestly elevated, stopping green tea extract before stimulation begins is not optional.

Dose-Separation Windows and Monitoring

Because the primary interaction concern with Ovidrel and EGCG is not a direct pharmacokinetic one, a dose-separation window (the strategy used with drugs that bind the same enzyme) does not apply here in the conventional sense.

The liver safety concern is cumulative, not acute. EGCG-related hepatotoxicity appears to be dose-dependent and related to total daily exposure over time, not to proximity to any single injection. This means that stopping green tea extract the morning of your trigger shot is insufficient. A washout period of at least 7 to 14 days is more appropriate, with some integrative medicine practitioners recommending a full cycle (28 days) of clearance before stimulation begins.

If you are already taking both and you are mid-cycle, do not abruptly attempt to manage this on your own. Call your reproductive endocrinologist's nursing line, report your supplement intake, and ask whether a same-day liver panel is warranted.

Who Should Not Take Green Tea Extract at All During Fertility Treatment

Certain women should avoid green tea extract not just during the trigger cycle but throughout their fertility workup:

• Women with any pre-existing liver condition, including NAFLD associated with PCOS or metabolic syndrome
• Women on letrozole or clomiphene for ovulation induction (both are CYP-metabolized; EGCG's CYP inhibition is more relevant here than with Ovidrel)
• Women who drink alcohol regularly (additive hepatotoxic stress)
• Women taking other supplements or medications with hepatotoxic potential, including high-dose niacin or acetaminophen at frequent intervals
• Women who have had abnormal liver function tests at any prior point in their fertility workup

A Note on the Evidence Gap

The direct combination of green tea extract and choriogonadotropin alfa has not been studied in a single published human trial. The guidance above is built from:

1. The mechanistic understanding of Ovidrel's glycoprotein pharmacology (renal clearance, not CYP-dependent)
2. Published case reports and systematic reviews on EGCG hepatotoxicity
3. In vitro data on EGCG effects on granulosa cells
4. Extrapolation from folate metabolism studies relevant to periconception safety

This is an evidence gap that matters. Women deserve to know when clinical guidance is extrapolated from indirect data rather than drawn from a direct trial. Until a well-designed study examines EGCG supplementation specifically in women undergoing hCG trigger cycles, conservative discontinuation during the cycle is the appropriate and proportionate recommendation.